Companies /Healthcare
Arcus Biosciences Inc
NYSE: RCUS Biotechnology
$24.19
▲ $0.36 (+1.51%) today
Markets open · 12:35pm ET

Arcus Biosciences (RCUS) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
67%
EPS beat rate
+14.81%
Avg. EPS surprise
Consecutive EPS beats
RCUS vs Market · 30-day return after each reportRCUSS&P 500
0%+20%+23.0%+6.9%Q1 25+22.0%+2.9%Q2 25+28.6%−1.0%Q3 25+5.7%−8.3%Q4 25−10.3%+0.7%Q1 26+2.6%−0.3%Q2 26
0%+20%Q1 25Q3 25Q1 26
RCUS EPS Trend · estimate vs actualEstimateActual
$-1.20$-0.80$-0.40$0.00$-1.01$-1.14Q1 25$-1.17$0.00Q2 25$-1.29$-1.27Q3 25$-1.01$-0.89Q4 25$-0.83$-1.02Q1 26$-0.81$-0.72Q2 26
$-1.20$-0.80$-0.40$0.00Q1 25Q3 25Q1 26
RCUS Revenue Trend · estimate vs actualEstimateActual
$0$50.0M$100.0M$150.0M$38.6M$28.0MQ1 25$32.9M$160.0MQ2 25$20.3M$26.0MQ3 25$26.4M$33.0MQ4 25$29.5M$17.0MQ1 26$22.0M$41.0MQ2 26
$0$50.0M$100.0M$150.0MQ1 25Q3 25Q1 26

How Often Does Arcus Biosciences Beat Earnings Estimates?

Arcus Biosciences beat EPS estimates in 4 of its last 6 reported quarters.

RCUS quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 Q2 2025 included a $143 million cumulative catch-up from license and development services revenue relating to pausing future development of etrumadenant and Gilead's related return of its license; Q2 2026 includes access rights revenues recognized related to the expiration of Gilead's option rights $-0.72 est. $-0.81 +11.58% $41.0M est. $22.0M +86.52%
Q1 2026 $-1.02 est. $-0.83 −23.26% $17.0M est. $29.5M −42.34%
Q4 2025 $-0.89 est. $-1.01 +11.59% $33.0M est. $26.4M +25.00%
Q3 2025 $-1.27 est. $-1.29 +1.57% $26.0M est. $20.3M +28.40%
Q2 2025 $0.00 est. $-1.17 +100.00% $160.0M est. $32.9M +386.96%
Q1 2025 $-1.14 est. $-1.01 −12.61% $28.0M est. $38.6M −27.47%

Figures from SEC filings and company reports. Not investment advice.